Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
20.82
+0.43 (2.11%)
At close: Oct 9, 2025, 4:00 PM EDT
20.83
+0.01 (0.05%)
After-hours: Oct 9, 2025, 7:58 PM EDT
Catalyst Pharmaceuticals Revenue
Catalyst Pharmaceuticals had revenue of $146.56M in the quarter ending June 30, 2025, with 19.44% growth. This brings the company's revenue in the last twelve months to $558.50M, up 28.55% year-over-year. In the year 2024, Catalyst Pharmaceuticals had annual revenue of $491.73M with 23.49% growth.
Revenue (ttm)
$558.50M
Revenue Growth
+28.55%
P/S Ratio
4.50
Revenue / Employee
$3,085,630
Employees
181
Market Cap
2.55B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 491.73M | 93.53M | 23.49% |
Dec 31, 2023 | 398.20M | 184.00M | 85.90% |
Dec 31, 2022 | 214.20M | 73.37M | 52.10% |
Dec 31, 2021 | 140.83M | 21.76M | 18.27% |
Dec 31, 2020 | 119.07M | 16.77M | 16.39% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CPRX News
- 16 hours ago - Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences - GlobeNewsWire
- 8 days ago - Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program - GlobeNewsWire
- 6 weeks ago - Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals - GlobeNewsWire
- 6 weeks ago - Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals - GlobeNewsWire
- 2 months ago - Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update - GlobeNewsWire
- 2 months ago - Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC) - GlobeNewsWire